CYBN:NYE- (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 8.9

Change

+0.08 (+0.91)%

Market Cap

USD 0.15B

Volume

0.32M
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 1.64B
RCUS Arcus Biosciences Inc

N/A

USD 0.91B
NUVB Nuvation Bio Inc

N/A

USD 0.77B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.41B
ADCT ADC Therapeutics SA

N/A

USD 0.14B
PLX Protalix Biotherapeutics Inc

N/A

USD 0.13B
OSTX OS Therapies Incorporated

N/A

USD 0.07B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.07B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.07B
ATNM Actinium Pharmaceuticals Inc

N/A

USD 0.05B

ETFs Containing CYBN

PSY 0.00 % 0.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.91% 67% D+ 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.91% 67% D+ 52% F
Trailing 12 Months  
Capital Gain -19.18% 70% C- 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.18% 70% C- 12% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 33.97% 82% B 92% A
Dividend Return 33.97% 82% B 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 337.80% 18% F 3% F
Risk Adjusted Return 10.06% 65% D 31% F
Market Capitalization 0.15B 85% B 31% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector